The post Pudgy Penguins Hit WIth Trademark Suit Over Merch appeared on BitcoinEthereumNews.com. PEI Licensing, the firm behind the clothing brand Original PenguinThe post Pudgy Penguins Hit WIth Trademark Suit Over Merch appeared on BitcoinEthereumNews.com. PEI Licensing, the firm behind the clothing brand Original Penguin

Pudgy Penguins Hit WIth Trademark Suit Over Merch

For feedback or concerns regarding this content, please contact us at [email protected]

PEI Licensing, the firm behind the clothing brand Original Penguin, has filed a lawsuit against the nonfungible token project Pudgy Penguins, alleging trademark infringement, dilution and unfair competition.

The lawsuit, filed Wednesday in a Florida federal court, focuses on Pudgy Penguins’ apparel, alleging the company uses a “family of penguin trademarks that are confusingly similar” to PEI’s marks.

“This action results from Defendant’s unauthorized use and attempted registration of various PENGUIN word and design trademarks in connection with apparel and related goods and services that are confusingly similar to PEI’s federally registered and famous PENGUIN and penguin design trademarks,” PEI said in its complaint.

An excerpt of PEI’s complaint comparing its Original Penguin brand to Pudgy Penguins’ merchandise. Source: CourtListener

PEI claimed in its lawsuit that it has used the “PENGUIN word mark at least as early as 1967” and first used a “penguin design” on apparel as early as 1956.

PEI Licensing said that it sent a cease and desist to Pudgy Penguins in October 2023, claiming its “products infringe and dilute PEI’s famous PENGUIN Marks.”

The letter also demanded that Pudgy Penguins abandon applications with the US Patent and Trademark Office “to register various PENGUIN marks,” according to the lawsuit.

PEI claimed that Pudgy Penguins had “misappropriated valuable property rights of PEI,” which was “likely to cause confusion or mistake, or to deceive members of the consuming public.”

PEI asked the court to order the USPTO to reject Pudgy Penguins’ applications and stop the company from allegedly infringing on its trademark. 

Related: SEC ends case against Justin Sun with $10M settlement

It also requested that Pudgy Penguins be ordered to destroy any products found “likely to be confused” with PEI’s trademarks and be awarded all profits from the sales of such products.

Pudgy Penguins’ legal chief, Jennifer McGlone, told Cointelegraph that the company “was surprised by the action, particularly as both parties had been engaged in productive discussions to resolve this matter privately.”

McGlone said the company had advanced applications with the USPTO and was “confident that PEI’s claims lack merit. The trademarks in question are visually distinct and serve entirely different audiences and markets.”

“We have the utmost confidence that we will prevail as Pudgy Penguins has already secured multiple trademark application approvals from the USPTO covering the Pudgy Penguins brand and related marks,” she said.

Meanwhile, the Pudgy Penguins X account posted a meme implying that its brand bears no similarities to Original Penguin.

Source: Pudgy Penguins

Magazine: Clarity Act risks repeat of Europe’s mistakes, crypto lawyer warns

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Source: https://cointelegraph.com/news/pei-licensing-files-trademark-infringement-lawsuit-against-pudgy-penguins?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Market Opportunity
Nietzschean Penguin Logo
Nietzschean Penguin Price(PENGUIN)
$0.005656
$0.005656$0.005656
+20.54%
USD
Nietzschean Penguin (PENGUIN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09